Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Study Identifier:
ALXN1210-DM-310
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
- Drug: Placebo
Date
Nov 2021 - Oct 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
- Drug: Placebo
Date
Nov 2021 - Oct 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).
Trial Locations
Location
Status
Location
Research Site
Irvine, California, United States, 92617
Status
N/A
Location
Research Site
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Research Site
Chicago, Illinois, United States, 60637
Status
N/A
Location
Research Site
Fairway, Kansas, United States, 66205
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21205
Status
N/A
Location
Research Site
Charleston, South Carolina, United States, 29425
Status
N/A